Can the first domestic new crown special medicine go on the market, can you take medical insurance?Is it effective for mutant strains?Detailed explanation →

On July 7, Teng Shengbo Pharmaceutical and its holding company Teng Shenghua announced that its new crown and antibody Anbawei's anti -anti -anti -anti -anti -anti -anti -anti -anti -antibody therapy was listed in China. Play. The medicine is also the first approved domestic new crown medium and antibody combination therapy drug.

What is the effect of this new crown special effect? Can the cost of treatment cost be bear? On the 8th, a reporter from the Beijing Evening News interviewed the relevant person in charge of Teng Shengbo Pharmaceutical and answered in -depth questions about the public's concern.

1. The price of new drugs is less than 10,000 yuan, why is it so expensive?

At present, the domestic listing model of Ambellimab and Romi Siwei's combination therapy has adopted an independent pricing model in China. Overseas, the business model of this drug is a government procurement model. For example, at the scale of the US government's procurement of millions of people, the government procurement price of each person is $ 1,200. The domestic pricing price of this domestic new crown special medicine is less than 10,000 yuan.

Luo Yongqing, president and CEO of Teng Shengbo Pharmaceutical, revealed that when the company was developing Ambellabe Ming and Romi Siweizabi, the company invested more than 200 million US dollars to ensure the smooth development and commercialization of business. He said that the price of new drugs should be comprehensively considering the dosage and the value of drug economy. When Teng Shengbo originally designed a new crown and antibodies, the virus might have occurred in the future, so a antibody was designed, not an antibody.

"Our current dose is 1000 mg of Ambalezab plus 1,000 mg 1,000 milligrams of Romi Siweizab, which is a total of 2,000 milligrams. It is the highest dose among all approval of neutralized antibodies at home and abroad." Luo Yongqing said.

2. Can this special effect medicine take medical insurance?

The price of nearly 10,000 yuan for this new crown special medicine is a heavy burden for many low -income families. However, the good news is that patients can take medical insurance settlement.

Since March 22 this year, many provincial and municipal medical insurance bureaus have successively incorporated the joint therapy of Anbawei's anti -anti -resistance and Romi Siwei's anti -anti -anti -solid therapy into the scope of the local medical insurance fund payment.

Another neutralized antibody, which has been approved in the world, Evusheld (Enbishi) this month has also been used in the international medical tourism zone of Boao Le City, Hainan through relevant policies. The price of two -shot injection of one -time injection is 13300 yuan, and medical insurance settlement cannot be used.

3. Can market supply be guaranteed?

In terms of production capacity, Teng Shengbo said that production plans will be formulated according to domestic and foreign market needs. Matching production capacity.

This new medicine has been used first in Shenzhen Third People's Hospital. At the same time, Tengsheng Pharmaceuticals commissioned China Resources Pharmaceutical, Sinopharm Holdings, and Shanghai Medicine. "They have the ability to cover any place across the country. Once there is a demand, they can be delivered quickly, and coverage is not a problem." Luo Yongqing said.

4. Why is the new medicine still effective for the Omikon mutation?

On July 6, the Prince of WHO Tan Desai said that 83 countries and regions were detected by BA.4, and BA.4 was detected in 73 countries and regions in 73 countries and regions. At present, BA.5 has replaced BA.2 to become the main poison in the world. The latest global new crown epidemic weekend announced by the WHO shows that the number of global new crown cases has increased for the fourth consecutive week, reaching the highest level since March this year.

The first domestic new crown special medicine faced the continuous mutant virus, showing a broad -spectrum. "The results just got on the 7th show that Anbawei's monoclonal anti -anti -anti -anti -anti -antibody therapy shows good virus inhibitory effects on the Omikon mutant BA.4 and BA.5." Shenzhen City "Shenzhen City Lu Hongzhou, Dean of the Third People's Hospital, introduced that the laboratory's fake virus research showed that the drug inhibited by 90%of the BA.4 or BA.5 virus was very low, which could meet the effective standards stipulated by the US Food and Drug Administration.

Why is this new crown -effect drug still effective in facing the continuous mutation of the new crown virus? Zhang Linqi, the head of the R & D team and a professor at the School of Medicine of Tsinghua University, revealed to reporters that everyone uses the "antibody pair" method to avoid virus escape, but the "antibody is right".

The two antibodies must cooperate with each other and can play a combination of fists, such as identifying different locations of the virus. Based on the refined research on the interaction of the entire virus and antibodies, the team finally screened the "antibody pair" that can coordinate each other in the 206 candidate antibodies to coordinate each other, and found the "best partner".

5. What is the actual clinical treatment effect?

"Earlier, neutralized antibody drugs developed by multiple multinational pharmaceutical companies lost their inhibitory activity on Omikon's mutant strains and were stopped clinical use." Lu Hongzhou said that the first domestic neutralized antibody drugs in suppressing Omikon Rong During the test, it was tested. It not only showed the ability to suppress Omikon BA.4 and BA.5 in the latest in vitro experiments, but also showed the clinical practice. 2 inhibitory effect.

During the past clinical treatment, Ambalezab/Romi Siwei's anti -combination therapy did show good results. Zhong Nanshan, an academician of the Chinese Academy of Engineering, said on the 8th that based on the observation of clinicians, the combined therapy could make the high virus load down rapidly within a relatively short time (2 to 3 days). The patient is very effective. 6. Do people who vaccinate the new crown vaccine still need neutralized antibody special medicine?

At present, vaccine, small molecular drugs, and neutralized antibody drugs play different roles in the response to the new crown epidemic.

"Neutral antibodies can make up for the lack of vaccine and small molecular drugs when they are used in immune fragile people." Yan Li, chief medical officer of Teng Shengbo Pharmaceutical, said that for those who are immune fragile, some of them may not be suitable for vaccination New crown vaccines, even if they are vaccinated, can not produce sufficient antibodies due to their weak immune response, and the vaccine cannot prevent the effect. For this part of the crowd, the injection and antibodies can produce a "immediate" effect.

7. Domestic new crown oral special effects is also expected to be approved. Will it affect the commercialization of neutralized antibody drugs?

Different from the mechanism of neutralizing antibodies to block the virus surface protein, the small molecular new crown drugs focus on the effect of eliminating the virus by interfered with the replication of the new crown virus itself, and the sensitivity to the virus variation is low. Small molecular drugs also have easy starting large -scale production, low cost, no need to operate by professionals such as medical staff, and will not cause burden on medical resources, suitable for the advantages of large -scale people to use. Therefore, it is the best choice to block the new coronal virus through oral small molecular drugs.

According to statistics, nearly 200 small molecular compounds around the world are conducting clinical trials for new crown pneumonia. Pfizer's new crown oral medication is approved to be listed in China in February this year. Many local pharmaceutical companies in China are also developing new crowned small molecules oral medications. The fastest progress is currently the real creature Azfding and the VV116 of Junshi creatures. Essence

If the domestic new crown oral special effects are approved, will it affect the commercialization process of Anbarab and Romi Siwitaba?

In this regard, Teng Shengbo's drug explained that for people with weak self -immunity, if the new crown virus is infected, there is a certain limitations of the treatment of small molecular drugs. "For example, an old man may also have other complications. Usually you need to take a variety of drugs. Can these drugs take at the same time as the new crown small molecular drug? This is a problem." Yan Li said that the injection and antibodies did not exist in the injection and antibodies. This trouble.

Professor Zhang Linqi said that the combination therapy of Anbawei's anti -anti -Romi Miki anti -anti -combination therapy was very fast, and the injection could be maintained for a long time in the body. Compared with the treatment of small molecular drugs for 5 to 7 days, neutralized antibodies 3 weeks after injection can still maintain a sufficient concentration of killing the virus in the body.

The research data given by Dean Lu Hongzhou also proves that the use time of the combination therapy is relatively loose. "The earlier the small molecule antiviral drugs, the better the effect. Generally, it can be used within 5 days. The combined therapy can still be effective within 6 to 10 days. The patient's clinical adaptation range is relatively wide."

8. What role can neutral antibody drugs play on blocking epidemic transmission?

"A keyword of neutral antibody is neutral." Yan Li said that after the combination of antibodies and viruses, it can quickly reduce the virus concentration and titer in the patient's body, and the infectious rate will naturally decrease. At the same time, the virus cannot be infected with new cells again in a combination of antibodies. Therefore, the first domestic new crown special drug can greatly reduce and block further infection.

Strictly claim that the small molecular drug may have a good effect after five days and the symptoms are reduced, but the symptoms may occur after about ten days of stopping the medicine, and there may be "Fuyang". "Patients think they will return to health, but this is not the case. It is a potential risk for groups and society, or cause further group dissemination. The antibody has a long period of half -life, reaching more than one month and two months, respectively. From this perspective, it can further effectively block and reduce the risk of group transmission.

Source: Beijing Evening News

PSAs

- END -